Literature DB >> 10092707

Radiation therapy for age-related macular degeneration.

A M Berson1, P T Finger, U Chakravarthy.   

Abstract

Neovascular age-related macular degeneration is the most common cause of severe irreversible blindness in the Western world in people older than age 50. Laser photocoagulation is the only proven treatment for this disease; however, fewer than 20% of patients are eligible for this treatment because the majority of choroidal neovascularization membranes are not visible by ophthalmoscopy or angiography. In addition, many patients elect not to undergo this treatment because laser treatment of subfoveal neovascular membranes results in immediate and permanent central visual loss. Several treatments are under investigation, including external-beam radiation therapy. There are multiple publications of early trials using radiation therapy, but to date there is only one randomized published study. This article reviews these trials and summarizes the status of radiation therapy as a treatment for macular degeneration.

Entities:  

Mesh:

Year:  1999        PMID: 10092707     DOI: 10.1016/s1053-4296(99)80005-8

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  4 in total

1.  [In Process Citation].

Authors: 
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

2.  Ten-year follow-up of eyes treated with stereotactic fractionated external beam radiation for neovascular age-related macular degeneration.

Authors:  Rupan Trikha; Lawrence S Morse; Robert J Zawadzki; John S Werner; Susanna S Park
Journal:  Retina       Date:  2011 Jul-Aug       Impact factor: 4.256

Review 3.  [Adjuvant radiotherapy during anti-VEGF in neovascular age-related macular degeneration].

Authors:  P Rating; M-A Freimuth; M Stuschke; N Bornfeld
Journal:  Ophthalmologe       Date:  2017-04       Impact factor: 1.059

4.  Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study.

Authors:  P T Finger; Y P Gelman; A M Berson; A Szechter
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.